Member Info for DugWalker

The most recent broker note suggested a target SP of circa 20p. It hasn't yet included revenues from Viura so I think we can anticipate a rerate substantially more than 30%. Not long to wait for results of well testing and confirmation of production flows and increased reserves.

No debt, cash generative and growing. Major producer with deep pockets taking a share of ownership of PXEN following due diligence of existing reserves may be suggestive of other interesting developments further down the line. Can't see this being range bound much longer.

@ Vincent

PXEN.

You need to make your decisions as you see fit mate. I'll be happy for you if my tip helps you recover some of your loss here.

I find it quite unbelievable that Burrows earns what he does. A complete charlatan of a CEO.

Massive 6-9 months coming PI. Annual profits will soon be roughly 50% of current mcap which is just bananas!

Excellent interview with one of your potential multi-bags . Link can be found on the relevant LSE share chat. (Link not posted by me but by another poster).

Correct we get 15% of production revenues until our capital investment is repaid, this then reverts to 7.5% of Viura production revenues to reflect our ownership.share of the field.

What I'm saying is that 7.5% of Viura will increase our current revenues (Selva + El Romeral by muc more than 7.5%h

When they can't sell existing tests shining a light on an academic publication smacks of yet more smoke and mirrors from this BoD. It also highlights the fact that they seem incapable of keeping their eyes on the ball. Sell the bloody tests you already have you idiots! We don't need additional development costs draining the dwindling finances.

7.5 % is our share of the Viura field. It equates to a significantly larger %age increase of our current production which is predominantly Selva plus a bit from El Romeral. It is game changing in terms of Prospex revenues and profits.

🤣

Muppet.

PI asked for help to recover some of his losses here and I gave him a tip ...

Will take a look! Thanks.

Hope it helps repair some of the damage done to your savings by Burrows et.al.

It's potentially a multi-bagger P.I

"Creaming it in" but now in tanker loads.

What a time to discover we are sitting on more gas than previously imagined.

Our revised cash flow from November will make the current valuation of PXEN look insanely low.

@PI

Hope you have taken time to enjoy today's RNS from PXEN.

Really hard to see BUPA riding to the rescue here NU.

It will have suited BUPA's marketing to align with breakthrough technology when the partnership with OBD arose. Zero or negligible cost to them in return for positive publicity. Sales of CiRT (and/or PSE) have not lived up to the promise that CiRT was to be offered to all BUPA customers being considered for immunotherapy. Shortly after the original announcement came another that stated that OBD was to hold a series of workshops for BUPA consultants (sound familiar?) to explain the benefits of the test to them. I find that a bit contradictory to the promise of offering the test to all relevant patients. Of course the experience of the US workshops is that oncologists have not been persuaded to adopt the technology and the only reason I can envisage is the absence of proper clinical validation. BUPA will not see the organisation of validation tests involving tens of thousands of patients as being a core competence or something they should invest in

Pro:

Great technology targeting huge markets.

Can be bought for loose change of most established pharma companies.

Cons:

No market pull for the tests has been established by current management.

No proper validation of any of the tests and failure to leverage the ongoing prostate screening study in UK means hefty investment of time (late to market as competitive tests emerge) and money will be required to convert IP to sales.

Due diligence needed will introduce additional delays.

In short, it's a gamble and businessmen prefer certainty.

Bamb,

My 'ramping' was based entirely on my support for and appreciation of a potential breakthrough technology. I started posting negatively only after the Burrows comedy show that made it obvious to me that OBD would not participate in the Transform project. It was then that the ineptitude of the company management team was layer bare. I was right in calling the outcome on Transform and I am confident in my remarks about NYS CLEPs impact on CiRT sales.

Balance 66,

Perhaps you are unaware that the use of LTD's has, for a long time been largely unregulated in the US. As such tests become more sophisticated and integral to critical medical decisions the FDA has moved to change that but it has been a slow process that has met with some political resistance. FDA has determined that it will soon require all LTD's to undergo proper scrutiny under their oversight. This is common knowledge and I raised a question on this with Burrows during one of his webinars Maybe a year or so ago. You should be able to find that and his reply on the corporate website.

The recent ruling by FDA requiring some LTD's comply with NYS CLEP is an interim and final step on the FDA's route towards full oversight.

The comment by OBD that NYS CLEP is much more rigorous than the oversight of the majority of LDT's whilst true, does not state the simple truth that any oversight is much more rigorous than the previous scenario. It is a classic smoke and mirrors statement suggestive of something significantly beyond the reality.

I do suggest you research this further NYS CLEP approval is not clinical validation it is recognitions that laboratory protocols and procedures meet required standards and yes, that the test basically does what is claimed but only on the evidence of a very small cohort. I will be very surprised if they sell significantly more tests because of this 'landmark decision'.

By the way the FDA document you link to refers people to the CLEP document I have posted for the detail of the NYS CLEP approval process so your assertion that the FDA document is the authority on this is plain wrong.

Probably nor a great decision on your part PI but since you have lost a small fortune here I wish you good luck.

Smart move Dusty.

What do you want him to show me again PI?

A statement from OBD that is ambiguous and potentially misleading?

I've given you the link to the organisation responsible for NYS CLEP. They are clearly telling you what it is. Maybe read it again and let it sink in